Literature DB >> 19152002

Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications.

Yoshihiko Segawa1, Saburo Takata, Masanori Fujii, Isao Oze, Yoshiro Fujiwara, Yuka Kato, Atsuko Ogino, Eisaku Komori, Shigeki Sawada, Motohiro Yamashita, Rieko Nishimura, Norihiro Teramoto, Shigemitsu Takashima.   

Abstract

PURPOSE: The purpose of this study was to prospectively assess the clinical implications of neuroendocrine (NE) differentiation in non-small-cell lung cancer (NSCLC) tumors.
METHODS: This study accrued subjects suspected to have lung cancer who underwent diagnostic bronchoscopy. Bronchoscopically-biopsied specimens were subjected to routine pathologic examination, and immunohistochemical studies were then performed if lung cancer was diagnosed. Chromogranin-A, synaptophysin, neural cell adhesion molecule, and Leu7 were used to demonstrate NE differentiation.
RESULTS: A total of 280 subjects were accrued to this study over a period of 2 years. Among them, 149 subjects were assessable for this study, and 130 were diagnosed as having NSCLC tumors (55 adenocarcinomas, 50 squamous cell carcinomas, 24 NSCLCs not otherwise specified, and 1 typical carcinoid). Large cell NE carcinoma was not observed in this study. Immunohistochemically, NE differentiation was detected in 16% of NSCLC tumors excluding typical carcinoid. By status of NE differentiation of NSCLC tumors, progression-free survivals were similar in 73 patients undergoing non-surgical treatment (positive, n = 10; negative, n = 63) and 43 patients undergoing surgical resection (positive, n = 8; negative, n = 35), respectively. Overall survival of patients with NE-positive tumors appeared to be favorable both for those undergoing non-surgical treatment and those undergoing surgical resection, though the differences in survival were not significant (P = 0.11 and 0.35, respectively).
CONCLUSIONS: NE differentiation was detected in 16% of NSCLC tumors in our study. However, the prognostic implications of the presence of this feature could not be clearly determined in this study.

Entities:  

Mesh:

Year:  2009        PMID: 19152002     DOI: 10.1007/s00432-009-0544-1

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  9 in total

1.  The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer.

Authors:  S L Graziano; R Mazid; N Newman; A Tatum; A Oler; J A Mortimer; J J Gullo; S M DiFino; A J Scalzo
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

2.  Revisions in the International System for Staging Lung Cancer.

Authors:  C F Mountain
Journal:  Chest       Date:  1997-06       Impact factor: 9.410

3.  Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer.

Authors:  Y Segawa; N Takigawa; M Kataoka; I Takata; N Fujimoto; H Ueoka
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-08-01       Impact factor: 7.038

4.  Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features.

Authors:  H H Berendsen; L de Leij; S Poppema; P E Postmus; A Boes; H J Sluiter; H The
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

5.  Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma.

Authors:  B G Skov; J B Sørensen; F R Hirsch; L I Larsson; H H Hansen
Journal:  Ann Oncol       Date:  1991-05       Impact factor: 32.976

6.  Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma.

Authors:  R E Kibbelaar; K E Moolenaar; R J Michalides; P C Van Bodegom; R G Vanderschueren; S S Wagenaar; K P Dingemans; D Bitter-Suermann; O Dalesio; N Van Zandwijk
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

Review 7.  The care of the lung cancer patient in the 21st century: a new age.

Authors:  Wade Smith; Fadlo R Khuri
Journal:  Semin Oncol       Date:  2004-04       Impact factor: 4.929

8.  Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience.

Authors:  R I Linnoila; S Piantadosi; J C Ruckdeschel
Journal:  Chest       Date:  1994-12       Impact factor: 9.410

9.  Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma.

Authors:  J T Schleusener; H D Tazelaar; S H Jung; S S Cha; P J Cera; J L Myers; E T Creagan; R M Goldberg; R F Marschke
Journal:  Cancer       Date:  1996-04-01       Impact factor: 6.860

  9 in total
  11 in total

1.  Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases.

Authors:  William Sterlacci; Michael Fiegl; Wolfgang Hilbe; Jutta Auberger; Gregor Mikuz; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2009-08-04       Impact factor: 4.064

Review 2.  Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?

Authors:  Andrew M Bellizzi
Journal:  Hum Pathol       Date:  2019-12-17       Impact factor: 3.466

3.  Increased neuroendocrine cells in resected metastases compared to primary colorectal adenocarcinomas.

Authors:  Marco Volante; Valerio Marci; Snezana Andrejevic-Blant; Veronica Tavaglione; Maria Carla Sculli; Marco Tampellini; Mauro Papotti
Journal:  Virchows Arch       Date:  2010-09-02       Impact factor: 4.064

4.  Expression of the xenobiotic- and reactive oxygen species-detoxifying enzymes, GST-pi, Cu/Zn-SOD, and Mn-SOD in the endocrine cells of colorectal cancer.

Authors:  Maya Gulubova; Tatyana Vlaykova
Journal:  Int J Colorectal Dis       Date:  2010-08-17       Impact factor: 2.571

5.  Breast metastasis from lung cancer: a report of two cases and literature review.

Authors:  Li Wang; Shu-Ling Wang; Hong-Hong Shen; Feng-Ting Niu; Yun Niu
Journal:  Cancer Biol Med       Date:  2014-09       Impact factor: 4.248

Review 6.  Multiple faces of pulmonary large cell neuroendocrine carcinoma: update with a focus on practical approach to diagnosis.

Authors:  Marina K Baine; Natasha Rekhtman
Journal:  Transl Lung Cancer Res       Date:  2020-06

7.  [Research on the relationship between non-small cell lung cancer with neuroendocrine differentiation and the biological characteristics and prognosis].

Authors:  Jun Zhang; Kai Zheng; Yan Guo; Peng Zhang; Zhongli Zhan
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-09

8.  Voltage gated sodium channels in cancer and their potential mechanisms of action.

Authors:  Madeline Angus; Peter Ruben
Journal:  Channels (Austin)       Date:  2019-12       Impact factor: 2.581

9.  Alterations in gene expression of proprotein convertases in human lung cancer have a limited number of scenarios.

Authors:  Ilya V Demidyuk; Andrey V Shubin; Eugene V Gasanov; Alexander M Kurinov; Vladimir V Demkin; Tatyana V Vinogradova; Marina V Zinovyeva; Alexander V Sass; Irina B Zborovskaya; Sergey V Kostrov
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

10.  Is the sum of positive neuroendocrine immunohistochemical stains useful for diagnosis of large cell neuroendocrine carcinoma (LCNEC) on biopsy specimens?

Authors:  Jules L Derks; Anne-Marie C Dingemans; Robert-Jan van Suylen; Michael A den Bakker; Ronald A M Damhuis; Esther C van den Broek; Ernst-Jan Speel; Erik Thunnissen
Journal:  Histopathology       Date:  2019-01-24       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.